DekaBank Deutsche Girozentrale’s Relmada Therapeutics RLMD Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-5,000	Closed	-$127K	–	1471
2021 Q3	$127K	Hold	5,000	–	–	﹤0.01%	1274
2021 Q2	$160K	Hold	5,000	–	–	﹤0.01%	1266
2021 Q1	$173K	Hold	5,000	–	–	﹤0.01%	1205
2020 Q4	$156K	Buy	+5,000	New	+$172K	﹤0.01%	1214

Other funds holding RLMD

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

DekaBank Deutsche Girozentrale's RLMD Position: Q4 2021 in Review

DekaBank Deutsche Girozentrale sold out of Relmada Therapeutics (RLMD) in Q4 2021, closing a stake of 5,000 shares — an estimated $127K sold.

DekaBank Deutsche Girozentrale first reported a position in RLMD in Q4 2020 and held it in 4 quarters. The position peaked at $173K in Q1 2021. 97 funds tracked by Wall St. Rank hold RLMD as of Q4 2021.

DekaBank Deutsche Girozentrale reported no remaining Relmada Therapeutics position as of Q4 2021 after selling out during the quarter.
DekaBank Deutsche Girozentrale sold 5,000 Relmada Therapeutics shares in Q4 2021, an estimated $127K.
DekaBank Deutsche Girozentrale first reported a position in Relmada Therapeutics in Q4 2020 and held it in 4 quarters.
DekaBank Deutsche Girozentrale's Relmada Therapeutics position peaked at $173K in Q1 2021.
97 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2021.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q4 2021, filed 2 Feb 2022.